If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
128
results.
Updated on
13/07/2025 [07:35:00]
Results 25 to 50 of 128
Absstract of: WO2025107068A1
It is provided a method of detecting inflammatory bowel disease (IBD) in a patient comprising the step of measuring in a sample of said patient protein expression from the sample, and determining from the measured expression the presence or absence in the patient of inflammatory bowel disease. The method comprises measuring the protein expression level measured of S100-A9, neutral ceramidase, serum albumin, chymotrypsin-C, protein S100-A4, alpha-1-acid glycoprotein 1, neprilysin, lactotransferrin, immunoglobulin lambda-like polypeptide 5, immunoglobulin heavy variable 4-28, protein S100-A8, chymotrypsin-like elastase family member 3A, IgGFc-binding protein, mucin-2, antithrombin-l 11, myeloblastin, zymogen granule membrane protein 16, annexin A2, glyceraldehyde-3-phosphate dehydrogenase, chloride anion exchanger, and/or a combination thereof.
Absstract of: PH12022550223A1
Provided is an antibody for the treatment or prevention of autoimmune diseases, comprising a heavy chain variable region represented by SEQ ID NO: 1 or SEQ ID NO: 24, and a light chain variable region represented by SEQ ID NO: 6, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 25.
Absstract of: EP4285988A2
The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
Absstract of: US2025154215A1
The present invention relates to a dual PRR-inhibiting peptide system consisting of TLR4- and RAGE-inhibiting motifs derived from S100A8 and S100A9 and conjugated with a CT peptide for colon-specific delivery. In human-derived monocyte THP-1 and mouse bone marrow-derived macrophages (BMDMs), S100A8/A9-derived peptides including TLR4 and RAGE-interacting motifs inhibit the binding of S100 to TLR4 or RAGE and the activation of the NLRP3 inflammasome in a dose-dependent manner. When the peptide according to the present invention is injected into mouse models of acute and chronic colitis, survival is significantly increased, and pathological damage to the colon is alleviated. In a mouse model of colitis-related colorectal cancer, when the peptide according to the present invention is injected, body weight is increased, tumor burden in the distal colon is decreased, and histological colon damage is significantly alleviated. When the peptide according to the present invention is injected into an oxaliplatin-resistant CRC xenograft mouse model, EMT-associated markers are reduced in tumor tissues and tumor growth is significantly inhibited.
Absstract of: US2025154591A1
The present invention is related to a method for determining or confirming chronic inflammatory intestinal disease or a risk thereof in a subject. The method comprises detecting the presence of keratin 7 (K7) mRNA or protein in a biological sample obtained from a subject.
Absstract of: AU2023364180A1
Provided herein is a peptide array comprising a plurality of flagellin peptides corresponding to highly conserved peptide regions. For example, the peptide array comprises a plurality of
Absstract of: CN119546632A
The present invention relates to a sandwich immunoassay for determining cross-linked collagen type V in a biological sample, and its use in identifying patients suffering from conditions associated with fibrosis, such as ankylosing spondylitis, inflammatory bowel disease, psoriasis and atopic dermatitis. The invention also relates to a kit for performing a sandwich immunoassay.
Absstract of: US2025144219A1
The present invention provides methods for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The methods can improve patient compliance, and thus, efficacy of the preparation. Specifically, the present methods make the gastrointestinal tract preparation composition palatable for the patient to consume. For example, for a patient preparing to undergo colonoscopy, the present methods make the bowel preparation solution taste significantly less salty.
Absstract of: US2025146075A1
Among the various aspects of the present disclosure is the provision of methods of diagnosing and treating inflammatory bowel disease (IBD) including ulcerative colitis (UC) or Crohn's disease (CD). In particular, the present disclosure provides in part a panel of IBD biomarkers useful in diagnosing and making treatment decisions. In addition, the present disclosure provides methods of treating IBD with a plasminogen activator inhibitor-1 (PAI-1) inhibitor or tissue plasminogen activator (tPA).
Absstract of: US2025146074A1
The invention relates to a method of determining whether a patient diagnosed with inflammatory bowel disease (will respond to 5-ASA therapy which includes the steps of: obtaining a stool sample from the patient, analyzing the sample for the presence of microbial acetyltransferase genes capable of converting 5-ASA to the clinically ineffective N-acetyl 5-ASA, if microbial acetyltransferase genes are not present in the sample, the patient will respond to 5-ASA therapy and such therapy should be administered; if microbial acetyltransferase genes are present in the sample, the patient will not respond to 5-ASA therapy and a second line therapy should be administered.
Absstract of: WO2025089672A1
The present invention relates to inflammatory bowel disease model production using patient-derived intestinal organoids, and use thereof, wherein the inflammatory bowel disease model produced by an optimized production method for inflammatory bowel disease model production can be used as a patient-customized bowel disease model by constructing an evaluation method for inflammatory bowel disease drugs.
Absstract of: WO2025089884A1
The present specification provides a method for providing information on ulcerative colitis by means of a processor, the method comprising: a step for receiving a Korean Ulcerative Colitis-Specific Questionnaire (K-UCSQ) score for an individual; and a step for determining an inflammatory bowel disease prognosis for the individual on the basis of the received K-UCSQ score.
Absstract of: WO2025089672A1
The present invention relates to inflammatory bowel disease model production using patient-derived intestinal organoids, and use thereof, wherein the inflammatory bowel disease model produced by an optimized production method for inflammatory bowel disease model production can be used as a patient-customized bowel disease model by constructing an evaluation method for inflammatory bowel disease drugs.
Absstract of: CN119896715A
The invention belongs to the technical field of traditional Chinese medicines, and discloses a traditional Chinese medicine composition for treating ulcerative colitis, which is characterized in that the traditional Chinese medicine composition is prepared by extracting the following raw medicinal materials in parts by weight: 5-15 parts of ginseng, 8-25 parts of cassia twig, 5-15 parts of nutmeg, 8-25 parts of poria cocos, 8-25 parts of roasted rhizoma atractylodis macrocephalae, 5-15 parts of rhizoma zingiberis, 10-30 parts of roasted semen coicis, 1-5 parts of indigo naturalis and 2-6 parts of coptis chinensis. According to the traditional Chinese medicine composition, ginseng, rhizoma atractylodis macrocephalae and poria cocos are used as monarch drugs together, and rhizoma atractylodis macrocephalae and poria cocos have the effects of replenishing qi to invigorate the spleen and eliminating dampness and excreting dampness together; semen coicis and rhizoma zingiberis are used as ministerial drugs and co-help the monarch drugs to resolve dampness and stop diarrhea; the traditional Chinese medicine composition has the functions of invigorating the spleen, replenishing qi, warming the kidney, stopping diarrhea, excreting dampness and removing toxicity, is mainly used for treating ulcerative colitis and irritable bowel syndrome (diarrhea type) clinically, can also be used for diagnosing'diarrhea 'and'stomachache' in traditional Chinese medicine, and can be used for treating
Absstract of: WO2025085928A1
This disclosure relates generally to methods for treating an inflammatory bowel disease ("IBD", e.g., Crohn's disease or ulcerative colitis) in a patient. More particularly, this disclosure relates to methods for selecting a therapy for treating a patient suffering from an IBD. In embodiments, the foregoing can also be used to assess the severity of the IBD. The predictive aspects of said methods can facilitate and expedite the identification and stratification of IBD patient populations that are responsive to treatment with a RIPK2 inhibitor. The foregoing methods can further include treating the IBD by administering a RIPK2 inhibitor to the patient.
Absstract of: WO2025085674A1
In one aspect, the present disclosure provides a method for selecting a subject having ulcerative colitis for treatment with ADS051, or a pharmaceutically acceptable salt thereof, the method comprising: (a) measuring MRP2 seRNA in a stool sample obtained from the subject; and (b) selecting the subject for treatment when the level of MRP2 seRNA in the stool sample exceeds a threshold value. In some embodiments, the subject has moderate or severe ulcerative colitis.
Absstract of: US2025129422A1
The invention relates to methods of monitoring treatment response, disease resolution, and disease progression in subjects having inflammatory bowel disease (IBD).
Absstract of: EP4541373A1
The present invention provides a therapeutic agent for sepsis and/or septic shock, comprising, as an active ingredient, a compound capable of suppressing phosphorylation of threonine at position 749 in human STAT1; a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for sepsis and/or septic shock, the method comprising selecting a compound capable of suppressing phosphorylation of threonine at position 749 in human STAT1; a therapeutic agent for colitis, comprising, as an active ingredient, a compound capable of promoting phosphorylation of threonine at position 749 in human STAT1; a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for colitis, the method comprising selecting a compound capable of promoting phosphorylation of threonine at position 749 in human STAT1; a therapeutic agent for systemic lupus erythematosus, comprising, as an active ingredient, a compound capable of inhibiting human STAT1; and a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for systemic lupus erythematosus, the method comprising selecting a compound capable of inhibiting human STAT1.
Absstract of: CN119857143A
The invention provides application of CD84 as a therapeutic target in preparation of drugs for preventing and treating inflammatory bowel diseases, and belongs to the technical field of biological medicines. The CD84 is applied to development, screening or preparation of drugs for preventing and/or treating inflammatory bowel diseases as a therapeutic target. According to the application, a dextran sodium sulfate (DSS)-induced inflammatory bowel disease classical animal model is taken as an experimental subject, and the anti-CD84 antibody is taken as a drug to block the biological function of CD84, so that the degree of DSS-induced mouse enteritis can be effectively relieved, the colorectal length can be recovered, and the secretion level of inflammatory factors can be reduced. Therefore, a new strategy is provided for targeted therapy of the inflammatory bowel disease by taking the CD84 as a therapeutic target.
Absstract of: CN119856706A
The invention provides a method for constructing a mouse model for selectively knocking out integrin alpha5 molecules in fibroblasts. The method comprises the following steps: hybridizing an integrin alpha5 knockout mouse (alpha5Flox/Flox) and a Col1a2-CreERT fibroblast tool mouse; the method comprises the following steps: constructing primers, respectively performing genotype identification on F2 generations of hybrid mice, screening simultaneously positive mice, and naming the mice as alpha5Flox/Flox; after the Col1a2-CreERT mouse is grown up, tamoxifen is continuously injected into the abdominal cavity of the Col1a2-CreERT mouse for 5 days to induce expression of Cre recombinase, and the alpha5-CKO mouse of which the integrin alpha5 molecule in the fibroblast is selectively knocked out is obtained. The invention also provides an application of the alpha5-CKO mouse, and the alpha5-CKO mouse is used for constructing an IBD (Inflammation Bowel Disease) mouse model. The mouse model construction method can be used for IBD progress research by applying the mouse model with the fibroblasts selectively knocking out the integrin alpha5 molecules, and an animal model basis is provided for research on the effect and mechanism of the integrin alpha5 molecules in IBD intestinal fibrosis progress.
Absstract of: CN119842979A
The invention relates to the technical field of biological nucleic acid detection, in particular to a primer combination, a detection method and a kit for detecting virulent strains and variants of infectious bursal disease viruses. The primer probe combination comprises three pairs of specific primer probes designed according to VP2 gene segments of a virulent strain, a variant 1 and a variant 2 of the infectious bursal disease virus, and the sequences of the three pairs of primers are as shown in SEQ ID NO: 1-9. The primer probe combination provided by the invention can achieve the purpose of distinguishing and detecting different strains of IBDV through fluorescent quantitative RT-PCR (Reverse Transcription-Polymerase Chain Reaction). The primer probe combination provided by the invention has the advantages of high sensitivity, strong specificity and the like, and provides a new effective detection means for rapid differential diagnosis of IBDV, epidemiological investigation and prevention and control of IBD clinically.
Absstract of: CN119837859A
The invention discloses an application of glabridin in preparation of related drugs for inhibiting epithelial-mesenchymal transition in inflammatory bowel diseases. In the epithelial-mesenchymal transformation process, epithelial cells lose cell polarity and intercellular connection, are transformed into mesenchymal cells in function and morphology, directly participate in fibroblast activation and extracellular matrix deposition and cause intestinal fibrosis, and are one of anti-fibrosis targets. According to the application of the glabrione in preparation of the medicine related to inhibition of epithelial-mesenchymal transition in the inflammatory bowel disease, provided by the invention, the expression change of epithelial cell markers Claudin-1 and E-cadherin caused by TGF-beta 1 and interstitial cell markers Vimentin, N-cadherin, Snail and alpha-SMA can be relieved, cell migration caused by TGF-beta is improved, and the epithelial-mesenchymal transition induced by TGF-beta 1 is inhibited. The research on the mechanism of action shows that by blocking a TGF-beta1/Smad2/3 signal channel and inhibiting AKT1 activation and inhibition of epithelial-mesenchymal transition, the application of the compound in inhibition of epithelial-mesenchymal transition and prevention of intestinal disease related fibrosis is prompted.
Absstract of: CN119846227A
The invention discloses a method, a system and equipment for evaluating the treatment effect of a CCDC71L inhibitor on radiation enteritis. It is found for the first time that knock-down of CCDC71L in human colorectal epithelial cells subjected to irradiation treatment can play a role in treating radioactive injury by regulating and controlling a lipid metabolism pathway and a ferroptosis pathway. On the basis, the invention provides a method, a system and equipment for evaluating the treatment effect of the CCDC71L inhibitor on the radiation enteritis for the field, so that a doctor is assisted in evaluating the treatment effect of a patient suffering from the radiation enteritis, and a clinician is guided to formulate an individualized treatment scheme for the patient.
Absstract of: US2025122569A1
The invention relates to methods of predicting a patient's responsiveness to treatment (e.g., vedolizumab treatment) for inflammatory bowel disease (IBD).
Nº publicación: WO2025079348A1 17/04/2025
Applicant:
TOHOKU UNIV [JP]
\u56FD\u7ACB\u5927\u5B66\u6CD5\u4EBA\u6771\u5317\u5927\u5B66
Absstract of: WO2025079348A1
It has been revealed that, from an analysis of the mechanism regarding the action of sulfasalazine which is a therapeutic drug for inflammatory bowel disease, an anti-inflammatory action occurs by increasing intracellular glutamate. As a result of a detailed analysis, it has been revealed that a glutamine synthetase inhibitor or an xCT inhibitor which increases intracellular glutamate has a therapeutic effect on inflammatory bowel disease. Further, it is considered that a compound that suppresses expression of a glutamine synthesis inhibiting enzyme or xCT also has a therapeutic effect. An xCT inhibitor or a glutamine synthetase inhibitor is useful as a prophylactic/therapeutic drug that is for inflammatory diseases, particularly inflammatory bowel disease, and that has no serious side effects such as immunosuppression.
BOPI
Electronic site
